Novartis’ CAR-T clears FDA panel with relative ease – PMLiVE
PMLiVE |
Novartis' CAR–T clears FDA panel with relative ease
PMLiVE In CAR-T therapy patients' cells are harvested and modified so they are more likely to seek out and destroy cancer cells expressing a particular antigen, in this case CD19. Once reprogrammed the T cells are infused back into the patient in order to … |
